Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHelical Bar Regulatory News (HLCL)

Share Price Information for Helical Bar (HLCL)

Share Price is delayed by 15 minutes
Get Live Data
182.40    -3.80 (-2.04%)
Bid:
180.60
Ask:
183.40
Spread: 2.80 (1.55%)
Market Cap: £222.26m
HLCL Live PriceLast checked at - London Stock Exchange

Intraday Helical Bar Share Chart

Launch Of Share Buyback Programme

Today 07:00

RNS Number : 2340H
Helical PLC
08 June 2026
 

 

8 June 2026

Helical plc

LAUNCH OF SHARE BUYBACK PROGRAMME

 

Helical plc (the "Company") is pleased to announce that it is today commencing a share buyback programme (the "Programme") to purchase ordinary shares of £0.01 each in the Company (the "Ordinary Shares") with an aggregate value of up to £5 million (excluding expenses). The Programme will commence immediately and shall continue until the earlier of 30 September 2026 and its completion.

 

The Company has entered into an irrevocable agreement (the "Agreement") with Peel Hunt LLP ("Peel Hunt") to undertake the Programme on the Company's behalf, with Peel Hunt making market purchases, as riskless principal, of the Ordinary Shares on the London Stock Exchange. Peel Hunt will make trading decisions under the Programme independently of the Company, subject to: (i) certain parameters agreed between Peel Hunt and the Company prior to the commencement of the Programme pursuant to the Agreement; and (ii) the Company's right to terminate the Agreement in certain customary circumstances. Any purchases of Ordinary Shares contemplated by this announcement will be subject to the terms of the Agreement.

 

Any purchases pursuant to the Programme shall take place in accordance with (and subject to the limits prescribed by) the Company's general authority to repurchase Ordinary Shares granted by its shareholders at the annual general meeting in 2025 (the "2025 Shareholder Authority") and any further authority to repurchase Ordinary Shares as may be granted by the Company's shareholders from time to time. The maximum number of Ordinary Shares that the Company is currently authorised to purchase under the 2025 Authority is 12,335,519. The 2025 Shareholder Authority will expire at the earlier of 17 October 2026 and the conclusion of the Company's 2026 AGM. Following the expiry of the 2025 Shareholder Authority, the continuation of the Programme will be conditional on the approval by shareholders of a resolution re-granting the directors' authority to purchase Ordinary Shares at the 2026 AGM and any further purchases will be in accordance with the terms of such approval.

 

The purpose of the Programme is to return surplus capital to shareholders. Ordinary Shares purchased pursuant to the Programme will be held in treasury and may be used to satisfy future obligations arising from the Company's employee share option programmes. Alternatively, they may be cancelled.

 

The Programme will be effected in accordance with applicable laws and the regulations of the UK Financial Conduct Authority (including Chapter 9.6 of the UK Listing Rules). The maximum price paid per Ordinary Share will be limited to be no more than the higher of (i) 105 per cent of the average middle market closing price of the Company's Ordinary Shares for the five business days before the purchase is made, and (ii) the higher of the price of the last independent trade and the highest current independent bid on the trading venue where the purchase is carried out. Due to limited liquidity in the Ordinary Shares and in order to proceed with the Programme in an effective manner, the Company's purchases of Ordinary Shares on any trading day may exceed 25 per cent. of the average daily trading volume of Ordinary Shares during the 20 trading days preceding the date of purchase. Accordingly, the Company does not intend to rely on the safe harbour provisions contained in Article 5(1) of the UK version of the Market Abuse Regulation (Regulation (EU) No 596/2014) as incorporated into UK domestic law by virtue of the European Union (Withdrawal) Act 2018.

 

The Company will announce all purchases of Ordinary Shares pursuant to the Programme by no later than the seventh daily market session following the calendar day on which such purchases occurred.

 

 

Enquiries:

 

Helical plc

Matthew Bonning-Snook (CEO)

Address: 22 Ganton Street, London, W1F 7FD

James Moss (CFO)

Website: www.helical.co.uk

 

Tel: 020 7629 0113

 

FTI Consulting

Email: Schelical@fticonsulting.com

Dido Laurimore

Tel: 020 3727 1000

Richard Gotla

Andrew Davis

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFVIRFIEIIR
Date   Source Headline
8th Jun 20267:00 amRNSLaunch Of Share Buyback Programme
3rd Jun 20262:00 pmRNSDirector/PDMR Shareholding
22nd May 20267:00 amRNSAnnual Results for the Year to 31 March 2026
14th May 20267:00 amRNSHelical and Orion complete 100 New Bridge Street
29th Apr 20267:00 amRNSNew 10,000 sq ft letting at The Bower
22nd Apr 20267:00 amRNSTrading Update
9th Apr 20262:00 pmRNSHolding(s) in Company
27th Mar 20262:15 pmRNSHolding(s) in Company
26th Mar 20264:00 pmRNSDirector/PDMR Shareholding
25th Mar 20263:00 pmRNSDirectorate change
5th Mar 202610:04 amRNSDirector/PDMR Shareholding
2nd Mar 20267:00 amRNSHelical agrees 20,000 sq ft letting at The Bower
27th Feb 20261:45 pmRNSHelical and PfL JV forward funds Southwark PBSA
12th Feb 20267:00 amRNS£220m loan for Paddington office development
10th Feb 20262:00 pmRNSNotice of Results
28th Jan 202610:15 amRNSDirector/PDMR Shareholding
27th Jan 20269:50 amRNSDirector/PDMR Shareholding
15th Jan 202611:32 amRNSDirector/PDMR Shareholding
5th Dec 202511:25 amRNSHolding(s) in Company
28th Nov 20255:00 pmRNSDirector/PDMR Shareholding
26th Nov 20257:00 amRNSResults for the Half Year to 30 September 2025
17th Oct 20257:01 amRNSNotice of Results
17th Oct 20257:00 amRNSTrading Update for the Period Since 1 April 2025
15th Sep 202510:25 amRNSTR-1 Notification of Major Holding(s) in Company
5th Sep 20257:59 amRNSUK Listing Rule 6.4.9R(2) Disclosure
4th Sep 202510:25 amRNSDirector/PDMR Shareholding
2nd Sep 20254:29 pmRNSTR-1: notification of major holdings
27th Aug 20257:00 amRNSMartina Malone appointed to the Board of Directors
8th Aug 202510:05 amRNSDirector/PDMR Shareholding
6th Aug 20251:30 pmRNSDirector/PDMR Shareholding
17th Jul 20251:24 pmRNSResult of AGM
17th Jul 20257:00 amRNSTrading Update
16th Jun 202511:56 amRNSNotice of Annual General Meeting & Annual Report
6th Jun 20257:00 amRNSDirector/PDMR Shareholding
21st May 20257:00 amRNSAnnual Results for the Year to 31 March 2025
15th Apr 20254:40 pmRNSDirector/PDMR Shareholding
11th Apr 20257:00 amRNSTRADING UPDATE
11th Apr 20257:00 amRNS£333 MILLION FORWARD SALE OF 100 NEW BRIDGE STREET
10th Mar 20254:53 pmRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNSPLANNING APPROVAL SECURED FOR SOUTHWARK SCHEME
19th Feb 202510:00 amRNSNotice of Results
17th Feb 20257:00 amRNSAppointment of Group Company Secretary
14th Feb 20257:00 amRNSDEVELOPMENT FUNDING AGREED FOR 10 KING WILLIAM ST
13th Feb 20257:00 amRNSJAMES MOSS TO SUCCEED TIM MURPHY AS CFO OF HELICAL
3rd Feb 20259:19 amRNSDirector/PDMR Shareholding
16th Jan 20258:59 amRNSDirector/PDMR Shareholding
9th Dec 20247:00 amRNSChange of registered office address
2nd Dec 202412:06 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:55 amRNS2025 Interim Dividend Timetable Correction
26th Nov 20247:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.